An overview of the pharmacology of rocuronium bromide in experimental animals

Eur J Anaesthesiol Suppl. 1994:9:9-15.

Abstract

In various animal species anaesthetized with a-chloralose (cats and pigs) or pentobarbitone (Beagle dogs and Rhesus monkeys), rocuronium has been shown to be a readily reversible, non-depolarizing neuromuscular blocking agent with a similar duration of action as vecuronium but a 6-10 fold lower potency. The outstanding features of its action is rapidity of onset. It is not expected to have any marked cardiovascular or autonomic side-effects when used in the neuromuscular blocking dose range. There is no evidence of any selective pre-junctional effect and there is no clinically relevant inhibition of acetycholinesterase. Screening in rats has not demonstrated any oestrogenic, androgenic, anabolic, glucocorticoid-like or gonad-inhibiting properties, although there was a slight increase in pituitary weight in male rats.

MeSH terms

  • Acetylcholinesterase / metabolism
  • Androstanols / pharmacology*
  • Anesthesia
  • Animals
  • Cardiovascular System / drug effects
  • Cats
  • Dogs
  • Female
  • Humans
  • Macaca mulatta
  • Male
  • Neuromuscular Junction / drug effects
  • Neuromuscular Junction / physiology
  • Neuromuscular Nondepolarizing Agents / pharmacology*
  • Rats
  • Rocuronium
  • Swine
  • Synaptic Transmission / drug effects

Substances

  • Androstanols
  • Neuromuscular Nondepolarizing Agents
  • Acetylcholinesterase
  • Rocuronium